The retinoblastoma tumor suppressor protein and its family members, p107 and p130, are major regulators of the mammalian cell cycle. They exert their growth suppressive eects at least in part by binding the E2F family of transcription factors and inhibiting their transcriptional activity. Agents that disrupt the interaction between Rb family proteins and E2F promote cell proliferation. Here we describe the characterization of a novel interaction between Rb family proteins and a potential tumor suppressor protein, prohibitin. Prohibitin physically interacts with all three Rb family proteins in vitro and in vivo, and was very eective in repressing E2F-mediated transcription. Prohibitin could inhibit the activity of E2Fs 1, 2, 3, 4 and 5, but could not aect the activity of promoters lacking an E2F site. Surprisingly, prohibitin-mediated repression of E2F could not be reversed by adenovirus E1A protein. A prohibitin mutant that could not bind to Rb was impaired in its ability to repress E2F activity and inhibit cell proliferation. We believe that prohibitin is a novel regulator of E2F activity that responds to speci®c signaling cascades.
Introduction
The progression of the mammalian cell cycle is precisely regulated by a combination of stimulatory and repressive elements (Bishop, 1991; Marshall, 1991) . The complex cell-cycle machinery mainly consists of cyclins, cyclin dependent kinases and their inhibitors, down-stream targets of the cyclin-dependent kinases which inlcude the Rb family of proteins and their down-stream targets, mainly the E2F family of transcription factors (Adams and Kaelin, 1996a; Cobrinik, 1996; Grana and Reddy, 1995; Kamb, 1995; Sherr, 1994; Sherr and Roberts, 1995; Slansky and Farnham, 1996; Weinberg, 1995) . It has been demonstrated that inappropriate activation of any of the positive acting elements or inactivation of the negative acting components can lead to neoplasia (Hamel and Hanley-Hyde, 1997; MacLachlan et al., 1995; Pines, 1995; Sutherland et al., 1995) . The components of the cell cycle machinery can respond to the appropriate extra-cellular signals and respond in the proper fashion facilitating proliferation, differentiation or apoptosis (Chellappan, 1994; Kohn, 1998; Lam et al., 1998; Lam and La Thangue, 1994; Wiman, 1993) .
The retinoblastoma tumor suppressor protein, Rb, and its family members p107 and p130 have been shown to be the major modulators of the G1/S transition in mammalian cells (Dyson, 1994; Ewen, 1994) . In normal mammalian cells, their function is regulated by phosphorylation mediated by cyclindependent kinases at precise stages of the cell cycle (Sherr, 1994) . It has been clearly established that cyclins D and the asssociated kinases cdk4 and cdk6 are involved in the phosphorylation of Rb and its consequent inactivation during G1 phase of the cell cycle, permitting the transition to S phase (Weinberg, 1995) . Cyclin E in conjunction with cdk2 also has been reported to inactivate Rb (Duronio et al., 1998; Lundberg and Weinberg, 1998; Taya, 1997) , but cyclin E/cdk2 can induce cell proliferation independent of the Rb protein also. In the case of p107 and p130 the picture is not very clear, but apparently cyclins D, E and their associated kinases are involved in their regulation (Beijersbergen et al., 1995; Xiao et al., 1996) . In addition, Cyclin A/cdk2 has been implicated in the inactivation of the p107 protein (Hauser et al., 1997; Faha et al., 1992; Shirodkar et al., 1992) . This scenario is supported by the ®ndings that Rb physically interacts with D-type cyclins whereas p107 binds to cyclins E and A Kato et al., 1993; Lees et al., 1992; Meyerson et al., 1992) .
Though phosphorylation is the main mechanism of inactivating Rb and its family members in normal mammalian cells, they can be activated by additional means. For example, inactivation of the Rb gene by mutation or deletion is widespread in a variety of human cancers (Cox et al., 1994; Cropp, 1995; Lee et al., 1988) . In addition to mutation, many viral oncoproteins like the E1A of adenovirus, large Tantigen of SV40 and the E7 protein of human papilloma virus have been found to physically interact with Rb family proteins leading to their functional inactivation equivalent to phosphorylation (Nevins, 1992 (Nevins, , 1993 (Nevins, , 1994 Whyte et al., 1989) . In addition to cyclins and viral oncoproteins, interactions with other cellular proteins contribute considerably to the function of the Rb family tumor suppressors (Taya, 1997) . The E2F family of transcription factors are especialy notable in this context, since they are believed to be the major down-stream targets of Rb proteins (La Thangue, 1996a; Nevins, 1992) .
Earlier observations had suggested that Rb protein physically interacts with E2F and represses its transcriptional activity (Bagchi et al., 1991; Chellap-pan et al., 1991; Hiebert et al., 1992) , and this is a major component of Rb-mediated growth regulation (Qin et al., 1995; Beijersbergen and Bernards, 1996) . It is now apparent that Rb binds to the transcriptional activation region of E2F (Helin et al., 1992; Kaelin et al., 1992) , and the Rb-mediated inhibition of E2F involves histone de-acetylases (Brehm et al., 1998; Luo et al., 1998; Magnaghi-Jaulin et al., 1998) . The Rb family members show a certain degree of preference to dierent E2Fs, with Rb binding to E2Fs 1, 2 and 3 and p107 and p130 binding to E2Fs 4 and 5 (Beijersbergen and Bernards, 1996; Cobrinik, 1996) . Many of the genes that are required for cell cycle progression require E2F, and the over-expression of E2F1 has been found to induce S phase entry (Adams and Kaelin, 1996b; Johnson, 1993) . Repression of E2F by Rb is believed to prevent the expression of such genes required for S phase progression, which leads to the cell cycle block. Indeed, a variety of experiments strongly suggest that E2F is the main down-stream target of Rb protein and Rb exerts its growth suppressive eects to a great extent by inhibiting E2F activity (La Thangue, 1996; Qin et al., 1995; Weinberg, 1995) .
Earlier studies have shown that E2F function is regulated by Rb family proteins, cyclin A (Adams and Kaelin, 1996a) , the dimerization partners of E2F (Bandara et al., 1994; as well as the co-activator p300 . In many cases, the proteins associated with E2F have been found to change during cell cycle progression as well as dierentiation (Chellappan, 1994; Corbeil et al., 1995; Ikeda et al., 1996; Strom et al., 1998) . Studies from our laboratory had found that two dierent p130-E2F complexes appear upon the dierentiation of HO-1 melanoma cells (Jiang et al., 1995) . Similarly, p130-E2F complexes were the predominant E2F containing moieties in dierentiated U937 cells (Zhang and Chellappan, 1996) . The experiments described in this paper stem from our eorts to identify and clone any novel protein that may interact with p130 or other members of Rb family and regulate E2F function. We ®nd prohibitin, a potential tumor suppressor, to be able to bind Rb, p107 and p130 very eciently and modulate E2F function. Prohibition is a 30kD protein whose gene was originally cloned based on its ability to induce growth arrest in mammalian cells (Nuell et al., 1991) . the actual mechanism of prohibitin function is not yet known, and the results described in this paper provide potential mechanisms of prohibitin function. Since prohibitin has been shown to be associated with certain cell-surface receptors like the IgM receptor (Terashima et al., 1994) it could be involved in mediating cell cycle regulation in response to speci®c signal transduction pathways.
Results
Prohibitin interacts with Rb, p107 and p130 in vitro and in vivo A yeast two-hybrid system was used to screen for proteins that interact with human p130 protein. The full length human p130 fused to the LexA DNA binding domain was used as a bait to screen a HL60 cDNA/VP16-AD library as previously described (Junaief et al., 1994; Vojtek et al., 1993) . Out of 80 clones that were obtained in the screen, 26 were partially sequenced. Among the known genes that were obtained, the most interesting appeared to be a sequence corresponding to amino-acids 1 ± 157 of human prohibitin. We chose to focus our attention on this gene, since it has been reported to have tumor suppressive and anti-proliferative eects.
The same two-hybrid system was used to evaluate whether the interaction was speci®c (Figure 1) . A full length prohibitin cDNA was cloned into the pGAD-NOT vector as a VP16 AD fusion protein (Vojtek et al., 1993) and was screened for interaction with pBTM116-p130. A strong interaction was observed in the form of dense colonies, but there were no colonies observed on plates transformed with the control vector (pBTM116). All the observed colonies gave a positive color reaction for b-galactosidase staining. Interestingly, prohibitin showed an extremely weak binding to a mutant p130 carrying a C?F substitution in the pocket domain (Claudio et al., 1994 (Claudio et al., , 1996 , suggesting that an intact pocket domain is required for the interaction. As shown in Figure 1d , e and f, prohibitin interacts with Rb and p107 also quite eciently.
The ability of prohibitin to bind to the Rb family proteins was examined by an in vitro GST anity chromatography.
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S-labeled prohibitin was synthesized by in vitro transcription-translation in rabbit reticulocyte lysates and its ability to bind to GST fusions of Rb, p107 or p130 was assessed. It was found that prohibitin could bind eciently to all the three pocket proteins (Figure 2a ). This experiment along with the yeast two-hybrid results suggests that the interaction between prohibitin and the Rb family proteins is probably direct. Further, prohibitin could not bind to GST beads carrying mutations in the pocket domain of Rb or p130. In a similar experiment, in vitro synthesized adenovirus E1A, like prohibitin could Figure 1 A two-hybrid analysis of the prohibitin-p130 interaction. A full-length prohibitin gene fused to the VP16 transcriptional activation domain was checked for its ability to interact with a control vector (pBTM116; (a)) or the same vector carrying a wild-type or mutant p130 gene (b and c). The ability of prohibitin to interact with p130, Rb and p107 was assessed similarly (d, e and f) bind to Rb, p107 and p130, but not the mutant proteins. E2F1 on the other hand bound only to GSTRb beads as expected. Under similar conditions of binding, in vitro synthesized JNK1 protein could not bind to any of the beads, suggesting that the interactions we observe are speci®c events. These results support the earlier ®nding that prohibitin requires an intact pocket domain for interaction, similar to E2F or viral oncoproteins. Prohibitin was unable to dissociate E2F from Rb and Rb containing complexes, when in vitro synthesized prohibitin was added to whole-cell extracts (data not shown).
Attempts were made to verify whether prohibitin interacts with the Rb family proteins in vivo in mammalian cells. To verify this, whole cell extracts prepared from Daudi and Ramos cells were immunoprecipiated with antibodies to Rb, p107 and p130. The presence of prohibitin in the immune precipitates was examined by a Western blot analysis. As can be seen from Figure 2b , prohibitin was found to coimmunoprecipitate with Rb, p107 and p130. There was no prohibitin present in a control immuneprecipitate, where a c-myc antibody was used. These results were con®rmed by performing the IP-Western experiment in the opposite fashion: immunoprecipitation was done using an anti-c-myc antibody as control, or a prohibitin antibody, and the presence of Rb, p107 and p130 examined by Western blotting. As shown in Figure 2c , all the Rb family members could be detected in a prohibitin immunoprecipitate, but not in the c-myc control. One of the blots was stripped and probed for the presence of JNK1; we do not ®nd any JNK1 in the prohibitin IP lane, suggesting that the observed interactions were speci®c. Co-immunoprecipitation of prohibitin with Rb family proteins was also observed in other cell lines like U937, T47D etc. (data not shown). These ®ndings strongly suggest that prohibitin can interact with proteins of the Rb family in mammalian cells, and this interaction can be detected without over-expressing any components. Since prohibitin was found to bind to all the three pocket proteins, further studies were conducted mainly on Rb. Prohibitin can repress E2F transcriptional activity A variety of cellular and viral proteins that bind to the pocket domain of Rb family of proteins can aect the transcriptional activity of E2F . To examine whether prohibitin is also capable of modulating the function of E2F, we performed a series of transient transfection experiments. As shown in Figure 3a , transient transfection of E2F1 along with an E2CAT vector induced transcription very eciently in T47D cells (Figure 3, lane 2) . Co-transfection of prohibitin totally repressed the transcription induced by E2F1 (Figure 3, lane 3) ; prohibitin was as ecient as Rb in this aspect. Prohibitin could repress E2F1-mediated transcription in other human cell lines as well (Daudi, Raji, Ramos, ZR75-30, C33A etc; data not shown). Surprisingly, adenovirus E1A could not reverse prohibitin-mediated repression of E2F1 activity (Figure 3b, lane 6 ). This is in marked contrast to repression of E2F activity by Rb family proteins (Hiebert et al., 1992) ; as shown in Figure 3b , lane 4, E1A was able to reverse Rb-mediated repression of E2F completely under identical conditions. This might suggest that prohibitin may be repressing transcription mediated by E2F by a mechanism dierent from the one used by Rb. Supporting this hypothesis, we have not observed a direct binding of prohibitin to the activation domain of E2F1, unlike Rb (data not shown).
Interestingly, co-transfection of prohibitin could block the E1A from reversing Rb-mediated expression of E2F activity. As shown in Figure 3b , E1A could block Rb-mediated reversal of E2F (Figure 3b , lane 4), but had no eect on prohibitin induced repression ( Figure 3b , lane 6). When prohibitin was co-transfected along with Rb and E1A there was no detectable transcriptional activation (Figure 3b, lane 7) . This could imply that E1A is unable to reverse Rb-mediated transcriptional inhibition by Rb and prohibitin can withstand the eects of E1A. This also raises the possibility that prohibitin may block the E1A-mediated dissociation of E2F from Rb.
Prohibitin can target all transcriptionally active E2Fs
Since prohibitin was found to interact with all three Rb-family proteins, we decided to examine its ability to repress transcription mediated by dierent members of the E2F family. E2Fs 1 ± 5 are known to be transcriptionally active (Slansky and Farnham, 1996) unlike the recently-describe E2F6, which has a mainly repressive function (Trimarchi et al., 1998) . We focused our studies on E2Fs 1 ± 5. Co-transfection experiments performed in T47D cells show that prohibitin can repress transcription mediated by all the ®ve dierent E2Fs (Figure 4a ). In contrast, Rb can repress only E2Fs 1, 2 and 3 (Figure 4b ), as has been described previously (Beijersbergen et al., 1994; Cobrinik et al., 1993) . This supports the possibility that prohibitinmediated repression of E2F may involve mechanisms that are distinct from the ones used by Rb protein itself. It is also possible that prohibitin collaborates with endogenous p107 and p130 to repress E2Fs 4 and 5, which are not repressed by the Rb protein.
Prohibitin did not have any eect on transcription from a pSVbgal vector in any of the experiments, which was the internal control for transfection (b-gal values ranged from 0.12 ± 0.14 in T47D cells). This appears to suggest that prohibitin is probably acting on E2F speci®cally, and may not aect other transcription factors or aect promoters lacking an E2F binding site.
The speci®city of prohibitin-mediated repression was veri®ed by performing additional transient transfection experiments. Transfection of an E2-CAT vector carrying mutated E2F sites resulted in no detectable CAT activity; in contrast, transfection of an equal amount of wild-type E2-CAT vector gave rise to high amounts of CAT activity, showing that the promoter is being driven by the endogenous E2F transcription Figure 4 (a) Prohibitin can repress all active E2F family members. E2-CAT reporter was co-transfected with E2F1, 2, 3, 4 or 5 in the indicated lanes. Co-transfection of prohibitin could eectively repress all the ®ve E2Fs (lanes 7 ± 11). DP1 was cotransfected along with E2Fs 4 and 5 to obtain optimal transcription. (b) In contrast, Rb could repress onkly E2Fs 1, 2 and 3 as reported previously (lanes 6, 7 and 8). (c) Prohibitin cannot repress promoters lacking an E2F binding site. Cotransfection of prohibitin with an excess of E2-CAT reporter results in a loss of transcriptional activity (lane 4); in contrast, prohibitin has no eect on co-transfected AP1CAT or c-fos CAT. Transcription from the E2CAT is dependent on the E2F site since a reporter carrying a point mutation in this region has no activity (lane 1). Prohibitin had no eect on a pSVb-Gal vector factors (Figure 4c, lane 3) . Co-transfection of a prohibitin expression vector totally abolished this E2F site-dependent transcriptional activity, showing that prohibitin could repress the endogenous E2Fs as eciently as over-expressed extraneous E2Fs ( Figure  4c, lane 4) . In contrast to E2-CAT, over-expression of prohibitin had no eect on the transcriptional activity of a c-Fos CAT or an AP1-CAT vector (Figure 4c , lanes 6 and 8). Since these two promoters had no E2F binding sites, it is likely that the repressive eects of prohibitin are restricted to the E2F transcription factors and promoters driven by them. It is also apparent that the repression of E2F by prohibitin is not mediated by a repression of the basal transcriptional machinery, since the promoters lacking an E2F site could function eciently in the presence of prohibitin.
Endogenous prohibitin levels aect E2F activity
The ®nding that co-transfection of prohibitin can aect the transcriptional activity of E2F prompted us to examine whetehr the levels of endogenous prohibitin had an eect on E2F function. A Western-blot analysis of the levels of prohibitin in ten human breast cancer cell lines identi®ed three (BL15, BL19 and BL20; ZR 57 ± 1, BT474 and DU 4475 respectively) which had high levels of prohibitin (Figure 5a) , and three in which prohibitin was absent or extremely low (BL 11, 12 and 16; MDAMB157, MDAMB134VI and BT549 respectively). Four cell lines had intermediate levels of prohibitin (BL13, BL14, BL17 and BL18; MDAMB435S, ZR75-30, BT483 and T47D respectively). Attempts were made to compare the E2F activities in two cell lines, one having low and the other having high levels of prohibitin. BL15 (ZR75-1) and BL16 (BT549) cells were chosen for this purpose, since they could be transfected eciently. Increasing amounts of E2F1 was co-transfected with 1 mg of the E2CAT reporter in BL15 and BL16 cell lines. It was found that low levels (1, 2 or 3 mg) of E2F1 could not induce the transcription of the E2CAT vector in the BL-15 (ZR 75-1) cells which had high amounts of prohibitin; but 4 mg of E2F1 could eciently induce transcription (Figure 5b ). This showed that all the necessary co-factors for mediating transcription by E2F1 are present in the cell. In contrast, cotransfection of even 1 mg of E2F1 could eciently induce transcription in BL-16 (BT-549) cells, which had no detectable prohibitin.
We next examined whether prohibitin levels had any eect on a promoter that lacked E2F binding sites. Transfection of dierent levels of AP1-CAT showed that the level of transcription from this promoter was quite comparable in both the cell lines (Figure 5c ). This observation supports the earlier ®nding that prohibitin did not repress the AP1-CAT in a co-transfection assay. It appears that high levels of prohibitin in cells can indeed aect transcriptional activity of E2F1 and probably the expression of cellular promoters having E2F binding sites.
Binding to Rb correlates with repression of E2F activity
Experiments were designed to assess whether prohibitin binding to Rb correlates with the observed repression of E2F-mediated transcription. The strategy used was to map the region of prohibitin required for binding to Rb and to check whether mutants that cannot bind to Rb can inherit E2F function. Amino-terminal truncations of prohibitin were generated by PCR and the resulting genes were transcribed and translated in vitro. The ability of the dierent deletion mutants to bind to Rb was checked by a GST-binding assay as described.
As shown in Figure 6a , deletion of the ®rst 33 amino-acids of prohibitin has no eect on its ability to bind Rb; similarly, a truncation of up to 74 aminoacids did not abolish its Rb-binding. Extending the deletion to 116 residues totally impaired its ability to bind to Rb, suggesting that the Rb-binding region spans residues 74 ± 116. This was veri®ed by generating a mutant which had an internal deletion of the residues 74 ± 116. As shown in Figure 6a , deletion of these residues eliminated the ability of prohibitin to bind to Rb, suggesting that these residues are indeed necessary Prohibitin levels do not aect the transcriptional activity of an AP1CAT vector. Indicated amounts of AP1CAT were transfected into the same cell lines; there was comparable amount of activity at all levels of vector tested for binding to Rb. This span of amino-acids had no LXCXE motif which is present in many Rb-binding proteins. An analysis of the sequence showed 45% identity and 70% similarity to a region of RBP1, a known Rb-binding protein. Interestingly, three of the four point mutations of prohibitin reported in sporadic breast cancers fall within this span (Sato et al., 1992 (Sato et al., , 1993 .
The ability of the mutant d74 ± 116 to repress E2F-mediated transcription was examined by transient transfection assays. As shown in Figure 6b , the mutant that could not bind to Rb could not repress E2F-mediated transcription either; similar results were obtained with the mutant 116 ± 275 (data not shown). The correlation between binding to Rb and repressing E2F was veri®ed more directly. Wild-type or d74 ± 116 prohibitin that carried a myc-tag at the amino-terminal end were generated, and were co-transfected along with Rb into T47D cells. A Western blot analysis of the whole-cell extracts from the transfected cells show comparable expression of wild-type and mutated prohibitin (Figure 6c ). An immunoprecipitation of the extracts with an anti-myc antibody followed by a Western blot analysis using an anti-Rb revealed that the transfected wild-type prohibitin does indeed interact with Rb in vivo. There was no Rb present in a myc immunoprecipitate where d74 ± 116 was cotransfected ( Figure 6d ). Since the two extracts had comparable levels of Rb and myc-tagged prohibitin, it appears that there is a direct correlation between the ability of prohibitin to bind to Rb and to repress transcription. It is likely that prohibitin is also binding to p107 and p130, as observed in untransfected cells.
Prohibitin can suppress cell proliferation
Prohibitin has been demonstrated to be a strong suppressor of cell proliferation, but the mechanisms involved are not yet clear. Since we observed that prohibitin can associated with Rb and express E2F activity, we decided to examine whether there is a correlation between its association with Rb and growth restrictive eects. To evaluate this, two dierent human cell lines, T47D as well as ZR75-30, were stably transfected with a control pSV-NEO vector, or a pCDNAIII-Prohibitin vector, which carries a neomycin resistance marker. After selection in G418 for 14 days, the number of antibiotic resistant colonies was determined. As shown in Table 1 , transfection of wild-type prohibitin into T47D cells reduced the number of colonies 3 ± 4-fold, compared to the control vector. Similar results were obtained with ZR75-30 cells (data not shown); the magnitude of repression by prohibitin was comparable to that of Rb under similar conditions. Interestingly, the d74 ± 116 construct was signi®cantly impaired in repressing cell proliferation. Similar results were obtained with the 116 ± 275 mutant also (data not shown). Since these prohibitin mutants have been found to be impaired in Rb binding, it appears that there is a direct correlation between the ability of prohibitin to bind Rb, repress E2F and impart growth arrest. Figure 3a and the ability of a wild-type prohibitin or a prohibitin d74 ± 116 mutant to repress E2F1 activity was assessed. (c) Overexpression of myc-tagged prohibitin WT or d74 ± 116 mutant in T47D cells, as examined by a Western blot analysis using an antiprohibitin antibody. (d) Prohibitin d74 ± 116 mutant does not interact with Rb in vivo. T47D cells over-expressing WT or mutant prohibitin shown in c were transfected with Rb and the whole-cell extracts were immuno-precipitated with an anti-c-myc antibody. The presence of Rb in the immune-precipitates was assessed by Western blotting. The control lane had extracts from untransfected T47D cells Suppression of colony formation by prohibition requires Rb binding. T47D breast carcinoma cells grown in 35 mm dishes were stably transfected with the indicated vectors, and selected in antibiotic for 14 days. Colonies having 20 or more cells were counted. pCMV-Rb was co-transfected with pBABE-Puro to impart resistance; pCDNA3-prohibition, WT and d74 ± 116, carried neomycin resistance markers. Selection was done in Neomycin or Puromycin depending on the vectors transfected
Discussion
The studies described in this paper identify prohibitin as an Rb-binding protein which can modulate E2F activity quite eciently. The ®nding as such is intriguing, since prohibitin itself is strongly antiproliferative, and is interacting with known growth suppressor molecules. Our ®ndings suggest that interaction with Rb family proteins is probably necessary for prohibitin to arrest cell proliferation.
Prohibitin was originally cloned based on its ability to induce growth arrest in mammalian ®broblasts and HeLa cells (McClung et al., 1989; Nuell et al., 1991) ; later studies have shown that prohibitin-mediated growth arrest is due to a G1/S block (Liu et al., 1994; Nuell et al., 1991; Roskams et al., 1993) . Information on the molecular nature of prohibitin is rather scanty, and it has no discernable functional domains . Prohibitin is highly conserved in a variety of organisms ranging from yeast to man. In addition to regulation of mammalian cell cycle, it has been reported that prohibitin plays a role in inducing senescence, and can limit the proliferative life span of yeast . Speci®cally, deletion of the yeast prohibitin gene in haploid cells resulted in an increase of the yeast life span by about 30%, whereas its over-expression reduced the life-span by 20% (Franklin and Jazwinski, 1993) .
The potential role of prohibitin in human breast cancer has been evaluated. Sato et al. (1992) analysed DNA from 23 sporadic breast tumor samples for mutations in exons 4 and 5 of prohibitin. The results revealed the presence of four point mutations in exon 4; three were in the coding region, and the fourth was in the intron-exon junction (Sato et al., 1992) . Apparently, mutations in the prohibitin gene in exon 6 have also been detected by a SSCP analysis, though the nature of this alteration is not known (Sato et al., 1992 ). An analysis of 76 familial early-onset breast cancers did not identify any mutations, suggesting that prohibitin inactivation may not be a causative step for familial breast cancer but could be playing a role in the generation of sporadic cancers (Sato et al., 1993) . Our results indicate that three of the four prohibition mutations reported in exon 4 localize to the Rb binding domain we have mapped making it a possibility that prohibitin cooperates with Rb family members to act as a tumor suppressor.
It is interesting to note that prohibitin can interact with all the three Rb family proteins quite eciently despite lacking the canonical LXCXE motif which is present in many Rb binding proteins (Taya, 1997) . Despite the absence of this sequence, prohibitin binds to the pocket domain of Rb, p107 and p130, suggesting that probably an LXCXE motif is not essential for binding to the pocket. This is true for certain other Rbbinding proteins that have been described. In preliminary experiments in U937 cells, we do not ®nd the prohibitin-Rb interaction to be cell cycle regulated. Unlike many other pocket-binding proteins, prohibitin does not have a negative eect on Rb function; in other words, it does not inactivate Rb like E1A or cyclin D/cdk4. Prohibitin on the other hand can be imagined to enhance Rb function similar to another Rb binding protein, Brg1 (Junaief et al., 1994) . We have been unable to quantify any synergistic growth suppressive eect since both Rb and prohibitin have very strong anti-proliferative eects by themselves.
The ®nding that prohibitin can aect all the dierent E2F family proteins raises many possibilities. First, it is probably targeting a domain on E2F that is shared by all the dierent family members. Prohibitin seems to dier in this aspect since Rb shows a preference to E2F2 1, 2 and 3 and p107/p130 to E2Fs 4 and 5. Second, if prohibitin is repressing E2F activity through Rb, p107 and p130, it may be able to cover the entire spectrum of E2Fs. This could be one probable scenario, since prohibitin did not bind to E2F directly Figure 7 A model for prohibitin-mediated repression of E2F activity. In a normal situation, adenovirus E1A can dissociate Rb from E2F reversing the repressive eects of Rb. Prohibitin binds to a Rb molecule that is bound to E2F and probably recruits a corepressor. In the presence of prohibitin, E1A is unable to dissociate Rb from E2F or the co-repressor from prohibitin and hence is unable to reverse prohibitin-mediated repression of E2F in an in vitro GST-binding assay. It should be pointed out, though, that even if prohibitin is inhibiting E2F activity through the Rb protein, other mechanisms and domains of E2F may be involved in the repression.
The precise mechanism by which prohibitin represses E2F activity is not yet clear. One major dierence in the repression by prohibitin compared to the repression by Rb family members is that prohibitin-mediated repression cannot be reversed by adenovirus E1A protein. As has been well-established, Rb binds to the activation domain of E2F and E1A disrupts this interaction releasing free, active E2F. In the presence of prohibitin such an activation is compromised. It is possible that prohibitin is preventing the E1A-mediated dissociation of E2F from Rb; such a scenario is depicted in the model in Figure 7 . Alternately, E1A may also bind to the pocket domain of Rb but allows prohibitin and a potential co-repressor to inhibit E2F. We are currently evaluating the potential role of additional proteins like histone de-acetylases in the prohibitin-mediated repression of E2F activity.
There is a good correlation between the ability of prohibitin to bind to Rb, repress E2F activity and arrest cell proliferation. This is based on the observation that the prohibitin molecule that lacks the Rb-binding domain is unable to repress E2F as well as induce growth arrest. This is quite conceivable since E2F1 has been shown to be a strong inducer of cell proliferation and inhibiting its activity could be an eective means of arresting cell proliferation. It should be pointed out that in the case of Rb all the mutations in the pocket domain which impairs its ability to repress E2F eliminates the ability of Rb to arrest cell proliferation. Certain point mutations outside the pocket domain, though, can abolish the E2F binding without compromising the anti-proliferative function.
The results described here demonstrate that there are molecules that can negatively regulate E2F function in addition to the Rb family proteins. Such molecules appear to be distinct from Rb in the mechanism of repression of E2F as well as the spectrum of E2Fs they can regulate. It is very likely that the involvement of dierent classes of molecules in the regulation of E2F will enable this transcription factor to respond to a variety of dierent signaling cascades in an appropriate fashion. For example, it has been reported that prohibitin is associated with the IgM receptor in rat B-cells (Terashima et al., 1994) ; it may be envisaged that prohibitin may be involved in conducting signals from this receptor. Preliminary results suggest that prohibitin can respond to IgM signaling and its eects on E2F are compromised upon activation of this receptor (data not shown). Further studies on prohibitin and the mechanisms involved in its regulation of E2F will shed light on hitherto unknown mechanisms regulating cell cycle components.
Materials and methods

In vitro binding assays
GST fusions of Rb and p107 containing pocket and Cterminal domains, or the pocket domain of p130 were used in this study. The mutant GST-Rb lacked exon 21; the p130 mutant had a C894?F substitution. Full length human prohibitin was cloned into pPCR-II vector and linearized with XbaI for in vitro transcription using SP6RNA polymerase. Prohibitin mutants 33 ± 275, 74 ± 275 and 116 ± 275 were generated by PCR and transcribed similarly. The internal deletion mutant d74 ± 116 was generated by an overlap-extension protocol and cloned into the same vector. The resulting mRNAs were translated in rabbit reticulocyte lysates (Promega) in the presence of 35 S-methionine (New England Nuclear). Eight ml of synthesized polypeptide was incubated with glutathione beads carrying equal amount (90 mg) of GST fusion proteins in 200 ml protein binding buer (20 mM Tris pH 7.5, 50 mM KCl, 0.5 mM EDTA, 1 mM DTT, 0.5% NP-40, 3 mg/ml BSA) at 48C for 2 h. The beads were washed six times with 1 ml protein binding buer and eluted with 10 mM glutathione. Eluates were separated in a 10% SDS-polyacrylamide gel and visualized by autoradiography. The protein amount in control input lanes were approximately one-®fth of the total used in binding assay.
Yeast Two-hybrid interaction assay
A LexA-p130 fusion cloned into pBTM116 vector was used to screen an HL60 cDNA library in a two-hybrid assay in the yeast strain L40 (His , Ura 7 ), as previously described (Vojtek et al., 1993; Junaief et al., 1994) . To assess the interaction between prohibitin and Rb family proteins, human p107 cDNA containing the pocket domain and the C-terminal domain were cloned into pBTM116 vector as a LexA DNA binding domain fusion; pBTM116-Rb was similar, and was a gift from Dr Stephen Go. Full length human WT p130 or a point mutant with a C894?F substitution was cloned into pBTM116 as a BamHI ± PstI fragment. Full length human prohibitin gene was cloned into pVP16 as a BamHI ± EcoRI fragment. PBTM116 vectors carry selection markers for Ura and Trp, and pVP16 for Leu2. Positives for interaction were recon®rmed by transferring the colonies to a ®lter and performing as an in situ b-galactosidase assay.
Immunoprecipitation and Western blot analysis
Mouse monoclonal antibodies to Rb and c-myc were obtained from Oncogene Science; anti-p107 and -p130 antibodies were from Santa Cruz Biotechnology. The antiprohibitin rabbit-polyclonal antibody was a kind gift of Dr J Keith McClung. A goat anti-human IgG antibody was obtained from Southern Biotechnology Associates and used at 1 mg/ml to stimulate Ramos cells.
Whole-cell extracts were prepared by hypotonic shock followed by salt extraction, as described previously. 50 ± 200 mg of whole-cell extracts were treated with 5 ml of the appropriate primary antibody in a volume of 100 ml at 48C for 1 h. Three mg of Protein A-sepharose or Protein G Sepharose in 100 ml volume was then added and incubated for additional 1 h. The binding was performed in a buer containing 20 mM HEPES pH 7.9, 40 mM KCl, 1 mM MgCl 2 , 0.1 mM EGTA, 0.1 mM EDTA, 0.1 mM DTT, 0.1 mM NaF, 0.1 mM Na 3 VO 4 , 0.5% NP40 and 3 mg/ml BSA. The beads were washed six times with 600 ml of the same buer, boiled in 20 ml of SDS sample buer, and separated on 8 or 10% polyacrylamide gels. After semi-dry transfer to supported nitro-cellulose membrane, the blots were probed using the appropriate antibody. The proteins were detected using an ECL system from Amersham.
Transient and stable transfections
T47D human breast cancer cells were transfected by calcium phosphate precipitation method using standard protocols. Generally, 2 mg of plasmids were used unless noted otherwise, and a pSVbgal vector was included in all transfections. PCDNA3-prohibitin was generated by sub-cloning a full length cDNA as a BamHI ± XhoI fragment obtained from pCR-II vector; amino-terminal myc-tagged prohibitin was generated in a pMum vector and sub-cloned as a EcoRI/NotI fragment in pcDNA3 vector. Constructs pDCE2F1, pE2CAT and pSVRb have been described before. Transient transfections were performed in 100 mm dishes for 72 h; assays for CAT and b-galactosidase performed using standard protocols.
Stable transfections were performed on 35 mm dishes, each having approximately 10 000 cells. Selection in 1 mg/ml of Puromycin or 40 mg/ml neomycin was commenced 48 h after transfection. After 14 days of selection, cells were ®xed in 3.7% formaldehyde, stained with 0.5% crystal violet and colonies having 20 or more cells were counted. In all the transfections, Rb was co-transfected with a pBABE-Puro vector; Prohibitin constructs carried a Neomycin resistance marker.
